NEWS
Revvity’s new UK hub boosts Genomics England collaboration
Life sciences and diagnostics firm Revvity, has chosen Bruntwood SciTech’s Alderley Park as its newest UK hub, following on from securing a world- leading research collaboration with Genomics England on the Generation Study, in collaboration with NHS England As part of plans for a nationwide expansion, the provider of products and services in translational multi-omics technologies, biomarker identification, imaging, screening, detection and diagnosis, will be joining a thriving community of over 250 innovative drug discovery, biotech, medcomms, diagnostics, AI, digital health and beauty tech businesses at the campus. Revvity selected Alderley Park to help support its work and take advantage of the campus’ world-class specialist workspace infrastructure, amenities and power resilience. Revvity will now utilise almost 6,000 sq ft of custom designed and fitted CL2 open- plan laboratory space within its Mereside hub. It will also be accompanied with a state-of-the-art, latest generation backup generator to ensure security and continuity of research.
Revvity will also continue to
strengthen its connectivity to the NHS via Bruntwood SciTech’s joint venture partnership with Manchester University NHS Foundation Trust (MFT) and gain direct access to research, collaborations, sample supplies, and direct introductions to clinicians.
Chris Hughes, managing director,
North Europe at Revvity, said: “As our work with Genomics England enters an exciting new chapter, so do we. Our UK expansion is about more than simply establishing a presence, it’s about unlocking new opportunities for collaboration and innovation. With access to world-class laboratory infrastructure and unrivalled connectivity to the NHS collaborators and industry peers, our new Alderley Park base will be central to supporting the delivery of the Generation Study as one of the study’s extraction and sequencing collaborators. The Generation Study will help enable earlier diagnoses and better outcomes for newborns, while supporting our broader mission to push the boundaries of what’s possible in healthcare.”
8
Proof of concept for HIV vaccination
Researchers at Amsterdam University Medical Center (UMC) have taken a big step towards a vaccine for HIV after its first in-human assessment of germline-targeting strategy with a trimer displays positive results. Results of the group’s phase one trial have been published in the journal Science. “For a HIV-vaccine to work it should
induce broadly neutralising antibodies against all the diverse strains of the virus. We’ve seen that those who have been infected with HIV have been able to develop these antibodies but it’s incredibly challenging to trigger the body to produce these antibodies with a vaccination,” says study author Tom Caniels, postdoctoral researcher at Amsterdam UMC. Together with partners from Rockefeller
University, and ten other American partners, the Amsterdam-based research team set out to trigger this response by developing a vaccine that uses specifically engineered immunogens, known as germline targeting.
“Across the participants we saw an
immune response that indicates that we’re on the right track. We saw that we can target the cells that we need to target with atomic precision. The next step is to further stimulate these cells to secrete broadly neutralising antibodies,” says study co-author Rogier Sanders, Professor of Virology at Amsterdam UMC. If the team can reach their next goal it would continue their work to ultimately create a vaccine for HIV. Something that Sanders and his team have been working on since the turn of the millennium. n Caniels TG, Prabhakaran M, Ozorowski G, et al. Precise targeting of HIV broadly neutralizing antibody precursors in humans. Science. Published online May 15, 2025. doi:10.1126/
science.adv5572
‘London Cancer Hub’ plans submitted
Plans to create the London Cancer Hub, set to be the world’s leading district for cancer research and treatment, have been submitted to Sutton Council. Once built the new centre will create thousands of jobs and contribute £1.2 billion to the UK economy. Situated within Europe’s leading cancer
treatment centre, the proposals for the 12-acre site in Belmont sit adjacent to The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust. The plans – submitted by Aviva Capital Partners (ACP) and Socius will create approximately 1 million sq ft of additional state-of-the-art laboratory and research space.
The masterplan includes large-scale facilities for global pharmaceutical and life sciences companies, flexible incubator spaces for start-ups and collaborative office space to bring together researchers, clinicians and innovators in one connected ecosystem to drive forward cancer research breakthroughs.
The development was featured in the Mayor of London and London Councils’ Growth Plan and is forecast to deliver £1.2 billion (Gross Value Added) annually to the UK economy. It is also expected to create 340 jobs per year during
JUNE 2025
WWW.PATHOLOGYINPRACTICE.COM
construction and 3,000 direct jobs in operation, the majority of which will be in highly-skilled R&D and small-scale manufacturing related to life sciences. Building on the world-class research
already undertaken by The Institute of Cancer Research, London, and The Royal Marsden, the project is designed to create a more connected and inclusive district for cancer research. Professor Kristian Helin, Chief Executive of The Institute of Cancer Research, London, said: “The London Cancer Hub has great potential to enhance our scientific partnerships with companies in the pharmaceutical and life-sciences industries.”
A decision on the application is expected later in 2025, with on-site works scheduled to begin in 2026, subject to approval.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52
